Completely revised and updated for 2012, the Physicians¡¯ Cancer Chemotherapy Drug Manual 2012 is an up-to-date guide to the latest information on standard therapy and recent advances in the field. Written by world-class experts in clinical cancer therapeutics, this essential reference provides a complete, easy-to-use catalog of over 100 drugs and commonly used drug regimens¡ªboth on- and off-label¡ªfor the treatment of all the major cancers.
¡öRevised to reflect rapid advances in the field, incorporating treatment strategies and new drugs like Abiraterone acetate, Eributin, Ipilimumab, Romidepsin, Sipuleucel-T, and Vandetanib.
¡öA specific chapter focused on profiling antiemetic drug and antiemetic treatment regimens.
¡öDiagrams of drug structures and pathways for many of the agents.
¡öOffers a comprehensive discussion of clinical pharmacology, special considerations, indications, and dosages.
¡öCovers toxicity and drug¨Cdrug interactions.
¡öA section on chemotherapy regimens for all major cancers.
¡öProvides an overview of the basic principles of cancer drug therapy.
¡öContains an easy to load and use CD version.
¡öMobile versions of Physicians¡¯ Cancer Chemotherapy Drug Manual are also available for iPhone and Android devices.
TABLE OF CONTENTS
¡öChapter 1 Principles of Cancer Chemotherapy
¡öChapter 2 Chemotherapeutic and Biologic Drugs
¡öChapter 3 Guidelines for Chemotherapy and Dosing Modifications
¡öChapter 4 Common Chemotherapy Regimens in Clinical Practice
¡öChapter 5 Antiemetic Agents for the Treatment of Chemotherapy-Induced Nausea and Vomiting
ABOUT THE AUTHOR(S)
Edward Chu, MD-Professor of Medicine, Chief, Division of Hematology-Oncology, Deputy Director, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania
Dr. Edward Chu is a Professor of Medicine, Chief of the Division of Hematology-Oncology, and Deputy Director at the University of Pittsburgh Cancer Institute. He received his MD degree from Brown University, where he also completed his residency training in Internal Medicine Residency. He then went to the National Cancer Institute in Bethesda, MD for fellowship training in Medical Oncology. Following completion of his fellowship, he remained at the NCI as a Senior Clinical Investigator. In 1996, he was recruited as a Professor of Medicine and Pharmacology at the Yale University School of Medicine where he assumed the positions of Director of the VACT Cancer Center, Associate Director of the Yale Cancer Center, and co-Director of the Developmental Therapeutics Program at the Yale Cancer Center.
Dr. Chu is well-known for his basic research that has investigated the determinants of resistance to the fluoropyrimidine class of anticancer agents. In particular, his group has made seminal observations on the regulation of expression of thymidylate synthase, a critical target in cancer chemotherapy, with specific focus on elucidating novel translational regulatory mechanisms. In addition, his group is actively involved in developing novel compounds and strategies for the treatment of colorectal cancer as well as other human malignancies. He has worked closely with a number of drug companies to develop novel agents, and these companies include Roche, Bristol-MyersSquibb, Astra Zeneca, Eli Lilly, Pharmacia, GlaxoSmithKline, Imclone, Vion, and Tularik. He serves on the scientific advisory boards of Advrx Pharmaceuticals, Celator, Etex, Phytoceutica, and Eximias, all of which are drug development companies.
He is the author of the Physicians¡¯ Cancer Chemotherapy Drug Manual, which is now in its sixth edition, and this drug manual includes a comprehensive review of all of the main drugs and drug regimens currently used in clinical practice for oncology. He is the founding Editor-in-Chief of the clinical journal Clinical Colorectal Cancer and is the Chairman of the International Colorectal Congress, which is an annual international meeting focusing on management and treatment of colorectal cancer.